Y-90 Fibroblast Activation Protein Inhibitor Therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Y-90 Fibroblast Activation Protein Inhibitor Therapy, covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) [Phase 2]